Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chiral switches.

G T Tucker1

  • 1Division of Clinical Sciences, University of Sheffield, Royal Hallamshire Hospital, UK. g.t.tucker@sheffield.ac.uk

Lancet (London, England)
|April 1, 2000
PubMed
Summary
This summary is machine-generated.

Chiral switching offers single enantiomer drugs for clearer pharmacology. However, the clinical benefits of these "pure" drugs over racemic mixtures require further investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and applications of a physiologically-based model of paediatric oral drug absorption.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2018
Same author

Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2016
Same author

Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years.

Journal of pharmaceutical sciences·2012
Same author

Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2011
Same author

Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction.

Current drug metabolism·2009
Same author

Development of CYP2D6 and CYP3A4 in the first year of life.

Clinical pharmacology and therapeutics·2007
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Area of Science:

  • Synthetic and analytical chemistry
  • Pharmacology
  • Medicinal chemistry

Background:

  • Chiral drugs exist as enantiomers (mirror images).
  • Racemic mixtures contain both enantiomers.
  • Different enantiomers can have distinct pharmacological effects.

Purpose of the Study:

  • To discuss the concept and implications of chiral switching.
  • To evaluate the potential clinical advances from single enantiomer drugs.

Main Methods:

  • Review of synthetic and analytical chemistry advancements.
  • Analysis of current and developing single enantiomer drugs.
  • Discussion of pharmacological differences between enantiomers and racemic mixtures.

Main Results:

Related Experiment Videos

  • Chiral switching allows for the development of single enantiomer drugs.
  • This process simplifies the understanding of drug pharmacology.
  • Several drugs have undergone or are undergoing chiral switching.

Conclusions:

  • Single enantiomer drugs offer a "pure" pharmacological profile.
  • The translation of chiral switching into significant clinical advances is yet to be fully determined.
  • Further research is needed to validate the clinical utility of chiral switches.